Congressional hemp restrictions threaten $28 billion industry, sending companies scrambling

A recent government funding bill includes a surprise provision effectively banning nearly all hemp-derived consumer products by setting a strict 0.4mg total THC limit per container, replacing the 2018 Farm Bill's 0.3% THC by weight definition. This new regulation is projected to wipe out 95% of the $28 billion hemp retail market, jeopardizing over 300,000 jobs and potentially shifting billions in sales to the black market due to continued consumer demand. Industry executives are preparing a lobbying push for federal standards, arguing prohibition will lead to lost tax revenue and increased safety risks, while also noting potential broader changes in cannabis regulation, including a possible reclassification of marijuana.

Analysis

The recently passed government funding bill introduces a stringent provision effectively banning most hemp-derived consumer products by setting a 0.4mg total THC limit per container, replacing the 2018 Farm Bill's 0.3% THC by weight definition. This regulatory shift is projected to eliminate 95% of the $28 billion hemp retail market within a year, jeopardizing over 300,000 jobs across the supply chain. States like Kentucky, Texas, and Utah are expected to face substantial economic fallout.

Industry executives, including Cronos Group CEO Michael Gorenstein, view this as a "total, all out, complete ban," warning that persistent consumer demand for THC products will likely drive billions in sales to an unregulated black market. This shift poses increased safety risks due to a lack of testing and age restrictions, alongside substantial losses in state and local tax revenue. The provision, championed by Sen. Mitch McConnell, aims to "restore the original intent" of the 2018 Farm Bill.

In response, the industry is preparing a comprehensive lobbying effort to advocate for federal standards, proposing a regulatory model involving the FDA for safety and the TTB for taxation and distribution, rather than prohibition. Concurrently, the Trump administration is considering reclassifying marijuana from a Schedule I to a Schedule III drug, a move that could ease sales and significantly alter the broader cannabis investment landscape. These impending changes create considerable uncertainty for future investments in the sector.

Key Decisions for Investors

• Investors should immediately re-evaluate their exposure to companies heavily reliant on the hemp-derived consumer product market given the projected 95% market contraction and strongly negative sentiment.
• Closely monitor the industry's lobbying efforts for federal standards and the potential reclassification of marijuana, as these developments could significantly alter the long-term investment landscape.
• Assess the potential for a growing black market and its indirect impact on legitimate cannabis companies, including increased competition from illicit products and challenges for law enforcement.
• For companies like Cronos Group (CRON), conduct a granular analysis of their specific exposure to the affected hemp segment versus their broader cannabis operations and strategic pivots.